ORIGINAL RESEARCH
Internal Medicine
doi: 10.25005/2074-0581-2024-26-1-10-17
PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME

L.A. SHPAGINA1,2, I.S. SHPAGIN1,2, L.D. KHIDIROVA1,3, A.A. VASILENKO1,2

1Novosibirsk State Medical University, Novosibirsk, Russian Federation
2City Clinical Hospital № 2, Novosibirsk, Russian Federation
3Novosibirsk Regional Clinical Cardiology Dispensary, Novosibirsk, Russian Federation

Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS).

Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program.

Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001).

Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients.

Keywords: Anxiety-depressive syndrome, depression, agomelatine, Valdoxan, post-COVID syndrome, COVID-19, arterial hypertension.

Download file:

References
  1. Humbert M, Kovacs G, Heper M, Badagliacca R, Berger R, Brida M, et al. ESC/ ESH 2022. Eur Heart J. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237
  2. Kobalava JD, Troitskaya EA. Chronotherapy of arterial hypertension: Current state of the problem and prospects. Russian Journal of Cardiology. 2023;28(3):5395. https://doi.org/10.15829/1560-4071-2023-5395
  3. Dzau VJ, Balatbat CA. The future of hypertension. Hypertension. 2019;74:450- 7. https://doi.org/10.1161/HYPERTENSION.119.13437
  4. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A meta-analysis of one group. J Med Virol. 2020;92(6):612-7. https://doi.org/10.1002/jmv.25735
  5. World Health Organization, 6 October 2021. https://www.who.int/newsroom/events/detail/2021/10/06/default-calendar/expanding-our-understanding-of-post-covid-19-condition-web-series-rehabilitation-care
  6. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. https://doi.org/10.1038/ s41598-021-95565-8
  7. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, et al. QT prolongation, torsades de pointes, and psychotropic medications: A 5-year update. Psychosomatics. 2018;59(2):105-22. https://doi.org/10.1016/j. psym.2017.10.009
  8. Jakobsen JC, Gluud Ch, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med. 2020;25(4):130. https://doi. org/10.1136/bmjebm-2019-111238
  9. Yan W, Wang Y, Huang Sh, Su X, Jiang Wenhui YR. Analysis of the use of antidepressants in patients from non-psychiatric departments in general hospital. Psychiatry Res. 2022;317:114823. https://doi.org/10.1016/j.psychres.2022.114823
  10. Frontera JA, Lewis A, Melmed K, Lin J, Kondziella D, Helbok R, et al. Prevalence and predictors of prolonged cognitive and psychological symptoms following COVID-19 in the United States. Front Aging Neurosci. 2021;13:690383. https:// doi.org/10.3389/fnagi.2021.690383
  11. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013;18(3):139-49. https://doi.org/10.1017/S1092852913000072
  12. Liu JM, Tan BH, Wu S, Gui Y, Suo JL, Li YC. Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection. J Med Vir. 2021;93(3):1304-13. https://doi. org/10.1002/jmv.26570
  13. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-70. https://doi.org/10.1056/NEJMc2008597.
  14. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020;95(8):e1060-e1070. https://doi.org/10.1212/WNL.0000000000009937
  15. Kamal M, Gbahou F, Guillaume J-L, Daulat AM, Benleulmi-Chaachoua A, Luka M, Chen P, Kalbasi Anaraki D, Baroncini M, la Cour CM, Millan MJ, Prevot V, Delagrange P, Jockers R. Convergence of Melatonin and Serotonin (5-HT) Signaling at MT2/5-HT2C Receptor Heteromers. J Biol Chem. 2015;290(18):11537- 46. https://doi.org/ 10.1074/jbc.M114.559542
  16. NICE. COVID-19 rapid guideline: Managing the long-term effects of COVID-19. Available online: https://www.nice.org.uk/ guidance/ng188 (accessed on 13 January 2021).
  17. Cassiani-Miranda C, Scoppetta O, Cabanzo-Arenas DF. Validity of the Hospital Anxiety and Depression Scale (HADS) in primary care patients in Colombia. General Hospital Psychiatry. 2022;74:102-9. https://doi.org/10.1016/j.genhosppsych.2021.01.014
  18. Ostroumova O, Goloborodova IV. Medikamentoznoe udlinenie intervala QT: rasprostranyonnost', faktory riska, lechenie i profilaktika [Drug-induced prolonged QT interval: Prevalence, risk factors, treatment and prevention]. Consilium Medicum 2019;21(5):62-7. https://doi.org/10.26442/20751753.2019.5 .190415
  19. Ivanov SV, Volel BA, Syrkina EA, Ternovaya ES, Troshina DV, Grubova MV, i dr. Retrospektivnoe arkhivnoe issledovanie po otsenke bezopasnosti primeneniya sovremennykh antidepressantov v kardiologicheskoy praktike [A retrospective historical study evaluating the safe use of modern antidepressants in cardiology practice]. Terapevticheskiy arkhiv. 2017;89(12):34-42. https://doi. org/10.17116/terarkh2017891234-42
  20. Sun X, Zhou M, Wen G, Huang Y, Wu J, Peng L. Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension. J Am Heart Assoc. 2021;5;10(1):e016364. https://doi.org/10.1161/JAHA.120.016364
  21. Jia P, Liu C, Wu N, Jia D, Sun Y. Agomelatine protects against myocardial ischemia reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Transl Res. 2018;10(5):1310-23.
  22. Starichkova AA, Tsygankova OV, Khidirova LD, Lukinov VL, Litvinenko PI, Starichkov AA. Kardiometabolicheskie osobennosti postkovidnogo sindroma u lits pozhilogo i starcheskogo vozrasta s komorbidnoy patologiey [Cardiometabolic features of postcovid syndrome in elderly and senile people with comorbid pathology]. RMZh. Meditsinskoe obozrenie. 2022;6(9):501-8. https://doi. org/10.32364/2587-6821-2022-6-9-501-508
  23. Novak Sarotar B, Lainscak M. Psychocardiology in the elderly. Wien Klin Wochenschr. 2016;128(Suppl 7):474-9. https://doi.org/10.1007/s00508-016- 1139-x
  24. Starichkova AA, Khidirova LD, Tsygankova OV, Lukinov VL. Kardiometabolicheskie i psikhokognitivnye osobennosti postkovidnogo perioda u bol'nykh s fibrillyatsiey predserdiy [Cardiometabolic and psychocognitive features of the postCOVID period in patients with atrial fibrillation]. Profilakticheskaya meditsina. 2023;26(4):43‑50. https://doi.org/10.17116/profmed20232604143
  25. Salah HM, Calcaterra G, Mehta JL. Renin-angiotensin system blockade and mortality in patients with hypertension and COVID-19 infection. J Cardiovasc Pharmacol Ther. 2020;25(6):503-7. https://doi.org/10.1177/1074248420947628
  26. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-64. https://doi.org/10.1124/jpet.103.051797

Authors' information:

Shpagina Lyubov Anatolievna
Doctor of Medical Sciences, Full Professor, Head of the Department of Hospital Therapy and Medical Rehabilitation, Novosibirsk State Medical University; Chief Physician, City Clinical Hospital № 2
ORCID ID: 0000-0003-0871-7551
E-mail: mkb-2@yandex.ru

Shpagin Iliya Semyonovich
Doctor of Medical Sciences, Associate Professor of the Department of Hospital Therapy and Medical Rehabilitation, Novosibirsk State Medical University; Cardiologist, City Clinical Hospital № 2
ORCID ID: 0000-0002-3109-9811
E-mail: mkb-2@yandex.ru

Khidirova Lyudmila Daudovna
Doctor of Medical Sciences, Professor of the Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine, Novosibirsk State Medical University; Cardiologist, Novosibirsk Regional Clinical Cardiology Dispensary
ORCID ID: 0000-0002-1250-8798
Е-mail: h_ludmila73@mail.ru

Vasilenko Anna Anatolievna
Applicant, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine, Novosibirsk State Medical University; Therapist at Outpatient Department, City Clinical Hospital № 2
ORCID ID: 0000-0002-6260-7102
E-mail: Vasilenko_anya@inbox.ru

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Khidirova Lyudmila Daudovna
Doctor of Medical Sciences, Professor of the Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine, Novosibirsk State Medical University; Cardiologist, Novosibirsk Regional Clinical Cardiology Dispensary

630091, Russian Federation, Novosibirsk, Krasnyy Ave., 52

Tel.: +7 (923) 1129218

Е-mail: h_ludmila73@mail.ru

Materials on the topic:
  1. COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
  2. GASTROINTESTINAL MOTOR FUNCTION IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS UNDERGOING JOINT REPLACEMENT
  3. THE EFFECTIVENESS OF OZONE THERAPY FOR ARTERIAL HYPERTENSION AND CONCOMITANT GASTROPATHY IN MINERS
  4. EVALUATION OF VENTILATION-PERFUSION RATIO IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  5. RELATIONSHIP OF THE STATE OF BIOMEMBRANES WITH INDICATORS OF ENDOTHELIUM DYSFUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  6. SCREENING OF RISK FACTORS OF CHRONIC NON-COMMUNICABLE DISEASES AMONG POPULATION OF THE HIGHLANDS IN TAJIKISTAN
  7. EVALUATION OF HELICOBACTER PYLORI IN PATIENTS INVOLVED TO CHRONIC DYSPEPSIA
  8. COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY
  9. FEATURES OF FREE RADICAL OXIDATION AND METABOLIC ACTIVITY OF VASCULAR ENDOTHELIUM IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  10. APPLICATION OF GASTROENTEROLOGICAL QUESTIONNAIRE GSRS IN DIAGNOSTICS OF GASTROINTESTINAL DYSFUNCTION IN LATE ELDERLY PATIENTS WITH ARTHROSIS ON THE DIABETES BACKGROUND

◄ Back to the list